Program Outline: the 14th Annual Meeting (as of Feb. 9, 2023). - Japanese Safety Pharmacology Society

Program Outline: the 14th Annual Meeting (as of Feb. 9, 2023).

Here is the program outline (as of February 9, 2023) of the 14th annual meeting.

Day 1: Fri. 2/17

10:00 〜	Opening Remarks by President of the 14th annual meeting, Notices from the 14th JSPS annual meeting
10:10 〜 11:00	Educational Lecture Roles of nonclinical safety data in clinical application Yuji Kumagai (Kitasato Clinical Research Center, Kitasato University School of Medicine) Session Chair: Atsushi Fujiwara (Ina Research Inc.), Hiroyuki Tashibu (Ina Research Inc.)
11:20 - 11:40	Exhibitor's Flash Talk Moderator: Erina Katayama (Sophion Bioscience Inc.), Takeshi Ishii (Drug Safety Testing Center Co., Ltd.)
11:40 - 12:10	Poster Presenters' Flash Talk Moderator: Takafumi Shirakawa (Astellas Pharma Inc.), Hiroyuki Ando (Ono Pharmaceutical Co.,Ltd.), Toshiki Kagawa (Mitsubishi Tanabe Pharma Corporation)
12:30 - 13:20	Lunchoen Seninar sponsored by Eurofins Discovery Central Nervous System Safety Screening: Practical Considerations for New Drug Development and Regulatory Science Chun-Yao Lee（Eurofins Panlabs Discovery Services Taiwan, Ltd.） Comprehensive Identification of Potential Cardiac Safety Liabilities Using a Totality of Evidence Approach Muthukrishnan Renganathan (Eurofins Panlabs Inc.） Moderator: Makoto Imatachi (Eurofins Discovery)
14:00 - 15:10	Symposium 1 (New Technologies) Current status of Microphysiological systems research in Toxicological science Hitoshi Naraoka, Ph.D., MBA (Non-clinical Biomedical Science, Applied Research & Operations, Astellas Pharma Inc.） Lung toxicology utilizing respiratory organoids Yuki Yamamoto, M.D., Ph.D (HiLung Inc.) Session Chair: Tomoharu Osada (LSI Medience Corporation), Keiichi Asakura (Nippon Shinyaku Co., Ltd.)
15:30 - 16:50	Workshop (Envisioning the implementation of ICH E14/S7B Q&As） Implementation of Best Practice in vitro hERG Assay under ICH E14/S7B Q&As: DSTC's efforts Hiroshi Matsukawa（Drug Safety Testing Center Co., Ltd.） Considerations for in vivo QT studies in terms of E14/S7B Q&As: the practical case of J-ICET ECG working group Ryuichi Komatsu (Chugai Pharmaceutical Co., LTD.) Panel Discussion Panelists: Hiroshi Matsukawa (Drug Safety Testing Center Co., Ltd) Ryuichi Komatsu (Chugai Pharmaceutical Co., LTD.) Satoshi Tsunoda (Pharmaceuticals and Medical Devices Agency) Takashi Yoshinaga (Eisai Co., Ltd.) Katsuyoshi Chiba (Daiichi Sankyo, Inc.) Session Chair: Tomohiko Taniguchi (Eisai Co., Ltd.), Taeko Kubo (Sumitomo Pharma Co., Ltd.)
- 17:00	Poster viewing area closed.

Day 2: Sat. 2/18

9:30 ～ 10:20	Invited Lecture Assessment of Blood Pressure and Hemodynamic Effects of Compounds in Safety Pharmacology Todd A. Wisialowski（Safety Pharmacology, Drug Safety Research and Development, Pfizer） Note: A pre-recorded presentation is delivered, but the presenter takes questions live from the audience on-line. Session Chair: Takashi Yoshinaga (Eisai Co., Ltd.), Keiichi Asakura (Nippon Shinyaku Co., Ltd.)
10:40 - 11:30	Q&A Session Moderator: Hirofumi Yokoyama (Nippon Kayaku Co., Ltd.), Hiroyuki Tashibu (Ina Research Inc.)
11:50 - 12:40	Luncheon Seminar sponsored by AnaBios Corporation Ensuring Drug Safety: How fit-for-purpose defines the use of human ex-vivo and iPSC-derived models in drug discovery. Blake Anson, PhD（Vice President Business Development, AnaBios Corporation） Modelator: Atsushi Sugiyama, MD, PhD (Professor of Pharmacology, Faculty of Medicine, Toho University / Director of Yamanashi Research Center of Clinical Pharmacology)
12:40 - 14:20	Poster Sessions Moderator: Takafumi Shirakawa (Astellas Pharma Inc.), Hiroyuki Ando (Ono Pharmaceutical Co.,Ltd.), Toshiki Kagawa (Mitsubishi Tanabe Pharma Corporation) Odd Numbers: 12:40 - 13:30 Even Numbers: 13:30 - 14:20
14:40 ～ 16:30	Symposium 2 (Central Nervous System) Brain-wide activation mapping highlights new neuronal ensembles in emotional control Atsushi Kasai (Graduate School of Pharmaceutical Sciences, Osaka University) Discovery of a dual orexin 1/orexin 2 receptor antagonist, lemborexant (Dayvigo), for the treatment of sleep disorders Taro Terauchi (Eisai, DHBL, Protein Integrity & Homeostasis Domain) Deciphering the Mysteries of Sleep: From fundamental mechanisms to real-world implementation Masashi Yanagisawa (International Institute for Integrative Sleep Medicine , University of Tsukuba) Session Chair: Masaki Honda (Chugai Pharmaceutical Co., Ltd.), Tohko Arai (Shionogi & Co., Ltd.)
16:40 - 16:50	JSPS Best Presentation Award Ceremony
16:50 - 17:00	Closing Remarks Greetings from the President of the 15th Annual Meeting, Taeko Kubo (Sumitomo Pharma Co., Ltd.)